Slingshot strengthens leadership with key executive hires

UK biotech Slingshot Therapeutics, part of the Syncona Accelerator, has expanded its senior team with the appointments of John Isaac as chief scientific officer and Bobby Soni as chief business officer. The move supports the company’s strategy to advance early-stage academic research into drug candidates ready for clinical development.

Dr Isaac succeeds founding CSO Richard Wooster, who becomes a non-executive scientific adviser and board member. A veteran neuroscientist with more than 30 years of experience, Dr Isaac previously served as CSO of AviadoBio and earlier led neuroscience innovation at Johnson & Johnson (NYSE: JNJ), Wellcome, and Eli Lilly (NYSE: LLY). He will oversee Slingshot’s scientific strategy and growth of its discovery pipeline.

Mr Soni, most recently CBO at Denmark’s BioInnovation Institute, brings more than 25 years in science, venture investing, and business leadership. His focus will be on business development, partnerships, and in-licensing, drawing on his experience at Novo Holdings, Maxygen, and Imperial Innovations.